Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the results of the Annual Ordinary Shareholders' Meeting held on July 6, 2018. The filing reports on corporate governance actions, including the approval of the 2017 financial statements, appropriation of losses, and the election of directors and auditors.
Key Financial Metrics
The filing references the 2017 fiscal year financial results approved by shareholders:
- Net Loss (2017): KCHF 25,868 (25.868 million Swiss Francs).
- Accumulated Loss Brought Forward: KCHF 32,558 prior to the 2017 loss.
- New Accumulated Loss Balance: KCHF 58,426.
The filing text does not provide specific values for revenue, operating cash flow, gross margins, debt levels, or liquidity ratios for the period.
Material Changes and Corporate Actions
Shareholders approved several material corporate actions:
- Board Composition: Re-election of Martin Velasco (Chairman), Peter Bollmann, Friedrich von Bohlen, Andrea Pfeifer, Detlev Riesner (with an age limit exception), Thomas Graney, and Douglas E. Williams. Werner Lanthaler was elected as a new member.
- Auditor Election: PricewaterhouseCoopers SA was elected for a one-year term.
- Capital Authorization: Shareholders approved a three-month extension of the authorization to increase share capital, replacing the resolution from April 27, 2018, if the initial resolution remains unimplemented.
Compensation and Governance
Shareholders approved the following maximum compensation limits for the period July 1, 2018, to June 30, 2019:
- Board of Directors (Non-performance cash): CHF 547,000.
- Board of Directors (Equity/Equity-linked): CHF 515,000.
- Executive Committee (Non-performance cash): CHF 1,807,000.
- Executive Committee (Variable cash): CHF 799,000.
- Executive Committee (Equity/Equity-linked): CHF 2,527,000.
The filing does not contain specific management commentary on future outlook, risks, or contingencies beyond the standard approval of the 2017 annual report.
Investor Verification Checklist
- Verify the full 2017 Annual Report and IFRS financial statements (referenced in Agenda Item 1) for detailed revenue and cash flow data not present in this summary.
- Review the attached press release (Exhibit 99.2) for any additional context on the share capital increase authorization.
- Confirm the status of the share capital increase resolution from April 27, 2018, to understand the conditions under which the new three-month extension applies.
- Monitor the implementation of the approved compensation packages for the Executive Committee and Board.